[go: up one dir, main page]

MX2012001718A - Composicion farmaceutica que incluye un ester de dha para ser administrada parenteralmente. - Google Patents

Composicion farmaceutica que incluye un ester de dha para ser administrada parenteralmente.

Info

Publication number
MX2012001718A
MX2012001718A MX2012001718A MX2012001718A MX2012001718A MX 2012001718 A MX2012001718 A MX 2012001718A MX 2012001718 A MX2012001718 A MX 2012001718A MX 2012001718 A MX2012001718 A MX 2012001718A MX 2012001718 A MX2012001718 A MX 2012001718A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
parenterally administered
composition including
dha ester
ester
Prior art date
Application number
MX2012001718A
Other languages
English (en)
Inventor
Peter Van Hoogevest
Elie Leverd
Elsa Kung
Mathew Leigh
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2012001718A publication Critical patent/MX2012001718A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para administrarse en forma be parenteral, incluyendo partículas de éster submicrónicas de ácido docosahexaenóico, dispersas en una fase acuosa utilizando una mezcla de al menos dos surfactantes seleccionados de entre a) al menos un éster de ácido polioxietileno graso y b) al menos un derivado de fosfolípido. La presente invención también se refiere al método para preparar la composición farmacéutica.
MX2012001718A 2009-08-11 2010-08-11 Composicion farmaceutica que incluye un ester de dha para ser administrada parenteralmente. MX2012001718A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0955612A FR2949063B1 (fr) 2009-08-11 2009-08-11 Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
PCT/EP2010/061701 WO2011018480A1 (fr) 2009-08-11 2010-08-11 Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale

Publications (1)

Publication Number Publication Date
MX2012001718A true MX2012001718A (es) 2012-04-02

Family

ID=42062409

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001718A MX2012001718A (es) 2009-08-11 2010-08-11 Composicion farmaceutica que incluye un ester de dha para ser administrada parenteralmente.

Country Status (22)

Country Link
US (1) US8753652B2 (es)
EP (1) EP2464335B1 (es)
JP (2) JP5847714B2 (es)
KR (1) KR101735861B1 (es)
CN (1) CN102470104B (es)
AU (1) AU2010283754B2 (es)
BR (1) BR112012003107A2 (es)
CA (1) CA2770262C (es)
ES (1) ES2566359T3 (es)
FR (1) FR2949063B1 (es)
GE (1) GEP20146088B (es)
HU (1) HUE026807T2 (es)
IL (1) IL217988A (es)
MA (1) MA33518B1 (es)
MX (1) MX2012001718A (es)
NZ (1) NZ598082A (es)
PL (1) PL2464335T3 (es)
RU (1) RU2535029C2 (es)
TN (1) TN2012000044A1 (es)
UA (1) UA108477C2 (es)
WO (1) WO2011018480A1 (es)
ZA (1) ZA201200714B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
WO2013123466A1 (en) * 2012-02-16 2013-08-22 Brightside Innovations, Inc. Dietary and nutritional compositions and methods of use
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
US11278493B2 (en) * 2018-12-10 2022-03-22 EternaTear, Inc. Ophthalmic formulations providing durable ocular lubrication

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
DE19609477A1 (de) * 1996-03-11 1997-09-18 Basf Ag Stabile wäßrige Solubilisate von Carotinoiden und Vitamine
RO120603B1 (ro) * 1996-08-22 2006-05-30 Research Triangle Pharmaceuticals Ltd. Compoziţie conţinând microparticule de substanţe insolubile în apă şi procedeu de preparare
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
WO2000078795A2 (en) * 1999-06-21 2000-12-28 Eli Lilly And Company Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1)
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
US20050214378A1 (en) * 2002-06-11 2005-09-29 Ethypharm Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
KR100482269B1 (ko) * 2002-10-08 2005-04-14 센츄론(주) 2,6-디이소프로필페놀을 활성성분으로 하는 수용액상의마취용 주사제 및 그 제조방법
CN1756545A (zh) * 2003-03-05 2006-04-05 索尔瓦药物有限公司 ω－3－脂肪酸在治疗糖尿病患者中的应用
US9060935B2 (en) * 2005-01-21 2015-06-23 Camurus Ab Pharmaceutical lipid compositions
FR2902659A1 (fr) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
CN101091890A (zh) * 2007-07-26 2007-12-26 沈阳药科大学 一种复合型乳化剂及用其制备的乳剂及其制备方法
CN101259102B (zh) * 2008-04-17 2011-05-25 湖北福星生物科技有限公司 一种微米级二十二碳六烯酸乳状液及其制备方法
CN101385714B (zh) * 2008-10-24 2011-07-27 苏州纳康生物科技有限公司 Dha脂质纳米粒的制备方法

Also Published As

Publication number Publication date
HK1170169A1 (en) 2013-02-22
FR2949063A1 (fr) 2011-02-18
JP2013501752A (ja) 2013-01-17
JP5847714B2 (ja) 2016-01-27
AU2010283754B2 (en) 2014-05-08
EP2464335B1 (fr) 2016-01-06
EP2464335A1 (fr) 2012-06-20
FR2949063B1 (fr) 2011-09-30
CN102470104B (zh) 2014-05-14
ZA201200714B (en) 2013-06-26
JP6050440B2 (ja) 2016-12-21
JP2016000742A (ja) 2016-01-07
AU2010283754A1 (en) 2012-03-08
PL2464335T3 (pl) 2016-06-30
NZ598082A (en) 2013-08-30
TN2012000044A1 (fr) 2013-09-19
CN102470104A (zh) 2012-05-23
IL217988A (en) 2016-05-31
ES2566359T3 (es) 2016-04-12
US8753652B2 (en) 2014-06-17
HUE026807T2 (en) 2016-07-28
CA2770262A1 (fr) 2011-02-17
KR101735861B1 (ko) 2017-05-15
RU2535029C2 (ru) 2014-12-10
IL217988A0 (en) 2012-03-29
BR112012003107A2 (pt) 2016-02-23
MA33518B1 (fr) 2012-08-01
UA108477C2 (uk) 2015-05-12
WO2011018480A1 (fr) 2011-02-17
KR20120047949A (ko) 2012-05-14
RU2012108049A (ru) 2013-09-20
CA2770262C (fr) 2016-12-06
GEP20146088B (en) 2014-05-13
US20120141563A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
NZ595204A (en) Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
MX2012001718A (es) Composicion farmaceutica que incluye un ester de dha para ser administrada parenteralmente.
CL2012001124A1 (es) Composición farmacéutica que comprende un extracto terapéutico concentrado, que comprende fosfolípidos en concentración de 60 a 99% y uso para tratar enfermedades cardiovasculares, reducir niveles de triglicérido, reducir colesterol ldl y aumentar colesterol hdl.
MX2010004820A (es) Mezcla lipidica para nutricion infantil.
MY187464A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy using eicosapentaenoic acid ethyl ester
NZ709083A (en) Eicosapentaenoic acid (epa) formulations
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
MX2012005744A (es) Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
PH12014500105A1 (en) Fatty acid compositions
WO2011097276A8 (en) Methods and compositions for treating arthritis with docosahexaenoic acid
PH12016500100B1 (en) Self-emulsifying composition of omega3 fatty acid
MX356427B (es) Emulsion que contiene hormona.
NZ734905A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX347573B (es) Composiciones y metodos para incrementar la estabilidad de aditivos para productos alimenticios.
EP2506848A4 (en) SUBSTANCES TO REDUCE THE IMPACT OF HARD CARDIAL EVENTS CONTAINING AN EXTRACT OF RED FERMENTED RICE AND A MULTIPLE UNSATURATED OMEGA-3 FATTY ACID OR DERIVATIVES THEREOF
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
MX2013002725A (es) Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco.
NZ747847A (en) Lipid compositions
CL2010001587A1 (es) Proceso de preparacion de un concentrado de etil esteres de acidos grasos omega-3 que comprende sobre el 80% en peso de dichos esteres en configuracion cis y sus dobles enlaces separados por una unidad metilenica.
MX360186B (es) Forma de dosificacion oral solida de derivado de testosterona.
MX2016003265A (es) Composiciones nanoparticuladas para administracion dirigida de farmacos lipofilicos y farmacos lipofilicos labiles en medio acido para quimioterapias de cancer y su preparacion.
MX2015007082A (es) Métodos de administración de composiciones que comprenden ácido docosapentanoico.
WO2011137160A3 (en) Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same

Legal Events

Date Code Title Description
FG Grant or registration